Resources

The FDA is rapidly scaling up the number of inspections it conducts of foreign drug making plants. This year, the agency plans to complete about 2,000 international inspections, and the evidence suggests that this number will continue to grow in FY13. Avoiding 483s in this environment may be tougher than in American plants, since the […]

In recent times, the FDA has stepped up its actions against pharmaceutical manufacturers, with 483s escalating to warning letters, warning letters to consent decrees far more quickly than it has in the past. What’s more, FDA officials have warned that it might go after individual executives and slap them with charges, which could impact or […]

During this August, FDA 483s month here at FDAzilla, we repost some of our favorite pieces related to 483s. Here’s one from the QA Pharm. Compliance to current good manufacturing practice (cGMP) regulations is, in fact, a part of normal pharmaceutical business that requires diligent management oversight. Just as it is with other business functions, […]

Today we have the privilege of interviewing former FDA investigator, LuisChavarria. After 30 years of conducting, managing, and supervising inspections, his insights are worthy of heavy consideration. 1. What do you think are the biggest misconceptions about FDA inspectors? I believe the biggest misconception about FDA inspectors is that they are there to “get you.” […]

We at FDAzilla are officially calling it. August is FDA Form 483s month. For the next 30 days, we will be posting a new article about FDA 483s every weekday – from insider insights to former investigator interviews to news synthesis to new data. As we’ve mentioned before, the FDA 483 is going through a […]

If you could ask the FDA anything about 483s or inspections anonymously, what would you ask? We’ve been in talks with the FDA, and it’s highly likely that they will be willing to answer a list of thoughtful questions from us. As the 483 has received increasing attention, it is in everyone’s best interest to […]

The first part of the month was relatively quiet, but then things really start hitting the fan last week.  Here are some of the latest stories related to FDA 483s: Of course, the big story of the month is Ranbaxy.  FiercePharma reported that it may have been a 483 that explains why Ranbaxy did […]

The FDA is watching you. Let FDAzilla help you watch them. We’ve talked to a lot of people who are seeing increased attention on FDA 483s. Industry professionals are looking to gain an edge as they prep for their next FDA inspection and to size up competitors and/or potential partners.Reporters are increasingly referring to specific […]

Here’s 10 recent stories that have hit our radar related to FDA 483s: FDA GMP inspectors cite 70% of dietary supplement firms within 3 years.   Frankly, I’m surprised that it wasn’t closer to 90%.  Average number of FDA 483 observations – 7. Impax hires 3 gurus to fix their manufacturing woes. A little unusual, […]

Now I know why we’ve been getting more calls/emails from financial institutions and hedge funds inquiring about FDA 483s – more and more investors are being introduced to the term during investor calls. While technical in nature, digging through a company’s history of 483s – especially when compared to competitor company’s profiles – can uncover […]